Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
Webster Brian Daniel reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies director and officer Brian Daniel Webster received an equity grant of 75,681 restricted stock units (RSUs), each settling into one common share at no purchase price. These RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026, contingent on his continued service. Following this grant, Webster is reported as beneficially owning 410,467 common shares, showing his overall equity stake including this new award.
Kestra Medical Technologies director and officer Brian Daniel Webster reported selling a total of 15,000 Common Shares in open-market transactions. The sales occurred on May 15, 2026 at weighted average prices of $21.4635 and $20.5287 per share. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Kestra Medical Technologies, Ltd. (KMTS) officer and director Brian Daniel Webster reported a proposed sale of 15,000 common shares, with an aggregate market value of $314,329.85 and an approximate sale date of May 15, 2026. He acquired the shares on January 21, 2026, in a restricted share issuance granted under the issuer's equity compensation plan. During the preceding three months, he reported sales of 15,000 shares on February 17 for gross proceeds of $384,020.06, 15,000 on March 17 for $304,123.49, and 15,000 on April 15 for $300,671.04. The date reported for plan adoption or giving of instruction, if relying on Rule 10b5-1, is September 29, 2025.
Kestra Medical Technologies director and officer Brian Daniel Webster reported an open-market sale of 15,000 common shares on April 15, 2026 at a weighted average price of $20.0447 per share. The trade was executed under a Rule 10b5-1 trading plan adopted on September 29, 2025, and Webster now holds 349,786 common shares directly.
Kestra Medical Technologies, Ltd. (KMTS) is the issuer in a notice covering officer and director Brian Daniel Webster’s proposed sale of 15,000 common shares, with an aggregate market value of $300,671.04 and an approximate sale date of April 15, 2026. The shares were issued to him as restricted shares under the issuer’s equity compensation plan on January 21, 2026. The notice lists a Rule 10b5-1 plan adoption date of September 29, 2025. It also reports three prior sales by Brian Webster: 15,000 common shares on January 15, 2026, for gross proceeds of $342,023.69; 15,000 on February 17, 2026, for $384,020.06; and 15,000 on March 17, 2026, for $304,123.49.
T. Rowe Price Associates filed an amendment to Schedule 13G reporting beneficial ownership of 5,968,664 shares of Kestra Medical Technologies common stock, representing 10.2% of the class. The filing lists sole voting power of 5,966,639 shares and sole dispositive power of 5,968,664 shares. The amendment is signed by Ellen York, Vice President, dated 04/08/2026.
Kestra Medical Technologies, Ltd. filed an automatic shelf registration on April 1, 2026 to offer and sell common shares from time to time under Form S-3 as a well‑known seasoned issuer. The prospectus permits offerings in amounts, at prices and on terms to be determined in each prospectus supplement, with sales commencing from time to time after the registration statement is declared effective.
The prospectus describes the company’s Cardiac Recovery System and its ASSURE WCD wearable defibrillator — which has been worn by over 33,000 patients as of January 2026 — and provides customary risk factors, tax discussions (Bermuda, Irish, and U.S. federal), plan of distribution options, and corporate governance and capital structure details. The prospectus discloses Nasdaq listing under the symbol KMTS and a last reported closing price of $19.93 per share on March 31, 2026.
Kestra Medical Technologies director Raymond W. Cohen bought 10,000 Common Shares of KMTS in an open-market purchase at a weighted average price of $19.98 per share. After this transaction, he directly owns 50,903 Common Shares. The footnote explains the trade prices ranged from $19.82 to $20.02 per share.
KESTRA MEDICAL TECHNOLOGIES, LTD. director and officer Brian Daniel Webster reported an open-market sale of 15,000 Common Shares on March 17, 2026 at a weighted average price of $20.2749 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating it was scheduled in advance rather than timed discretionarily. Following this sale, Webster continues to hold 364,786 Common Shares directly, showing he retains a substantial equity stake in the company.
KESTRA MEDICAL TECHNOLOGIES, LTD. reports a notice by officer and director Brian Daniel Webster of a proposed sale of 15,000 common shares, with an aggregate market value of $304,123.49, approximately March 17, 2026. The shares were issued to him as restricted shares under the issuer’s equity compensation plan on January 21, 2026. The notice lists September 29, 2025 as the Rule 10b5-1 plan adoption or instruction date. Common shares outstanding were 58,373,353.